ternspharma.com (TERN) - Price-to-Projected Revenue Ratio

Corporate emblem and logo of Terns Pharma (TERN)

High barriers to entry and stringent FDA requirements protect Terns Pharmaceuticals (TERN) from smaller players. This expected P/S chart for the company on GURU.Markets visualizes market expectations, where the 456.60 metric determines this level. Business value growth relies on the rollout of obesity and NASH drugs, and the active acceleration of clinical trials has now reached its peak.

TERN Terns Pharma: Market Cap to Expected Sales Ratio in the range 07/04/2022 - 04/01/2023

Financial and market metric breakdowns for Terns Corp (TERN)

- market price and analyst price targets:
Price Chart Terns Pharmaceuticals, Inc.|TERN - Fair Value Consensus
- market capitalization indicators:
Market Value Terns Corp|TERN - Business Value
- book value of equity indicators:
Net Assets per Single Share Terns Pharmaceuticals|TERN - Book Valuation of Business|Market Cap to Net Assets Ratio ternspharma.com|TERN - Aggregate Asset Value
- company total debt and liquidity indicators:
Debt to Equity Terns Pharmaceuticals|TERN - Long-Term Liabilities to Equity|Short-Term Debt to Capital Terns Pharmaceuticals|TERN - Aggregate Debt Obligations|Debts to Book Capitalization Terns Corp|TERN - Company Long-Term Debts|Company Short-Term Debt Terns Pharmaceuticals|Quick Liquidity ternspharma.com
- business earnings and investment ratios data:
TERN - Net Income|Projected Future Earnings Terns Pharmaceuticals|TERN - P/E Multiple|Forward P/E Multiple Terns Pharmaceuticals Inc|TERN - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Terns Corp|TERN - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Terns Pharmaceuticals|TERN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months ternspharma.com|TERN - Net earnings per one share growth for the current year|Earnings growth forecast for next year Terns Pharmaceuticals
- sales volume and revenue indicators:
TERN - Company Gross Revenue|Projected Sales Volume Terns Pharmaceuticals, Inc.|TERN - Market Cap to Revenue|Forward P/S Multiple Terns Corp
Summary company analysis:Terns Pharmaceuticals, Inc. TERN
Original product of Terns Corp

The prospects of Terns Pharmaceuticals (TERN) depend on the success of innovative drugs for the treatment of liver diseases. The forward price-to-sales valuation trend reflects the ratio of current market capitalization to expected sales, measuring the degree of market optimism. Sharp peaks on the chart signal that the asset is overbought and highlight risks of a deep correction. Amid intense competition with pharma behemoths, this indicator helps assess whether the premium for the company's future success is justified.

Competitors of Terns Pharmaceuticals

Price-to-Projected Revenue Ratio Phathom Pharmaceuticals, Inc. PHAT|Forward Price to Sales IRWD|CURX - Price-to-Projected Revenue Ratio|IMRN (Immuron Limited) - Market Cap to Projected Revenue|Evoke Pharma, Inc. (EVOK) - Price-to-Projected Revenue Ratio|ENTO - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple RDHL|PALI: Forward Price to Sales|Price-to-Projected Revenue Ratio Jaguar Animal Health (JAGX)|BIOR: Future Price to Revenue|Forward P/S Multiple MORF (Morphic Holding, Inc.)